Starpharma Holdings (ASX:SPL) Total Equity: A$21.48 Mil (As of Dec. 2025)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
52 GF Score
Price A$0.70
GF Value A$0.43
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Total Equity?

Starpharma Holdings ASX:SPL +0.72% 52 Total Equity is A$21.48 Mil as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 52/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Starpharma Holdings's total equity for the quarter that ended in Dec. 2025 was A$21.48 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Starpharma Holdings Total Equity Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Total Equity Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.30 48.39 34.82 28.12 19.00

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.45 28.12 23.17 19.00 21.48
ASX:SPL
52GF Score
Starpharma Holdings Ltd ASX:SPL
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Starpharma Holdings's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=25.421-6.423
=19.00

Starpharma Holdings's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=26.167-4.688
=21.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$21.48 Mil mean?
Starpharma Holdings (ASX:SPL) has a Total Equity of A$21.48 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Starpharma Holdings and its competitors.
Is Starpharma Holdings' Total Equity too high?
Starpharma Holdings' current Total Equity is A$21.48 Mil. Overall, Starpharma Holdings has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Total Equity compare to VRTX and REGN?
Starpharma Holdings' Total Equity of A$21.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Starpharma Holdings and its competitors. Starpharma Holdings's current Total Equity is A$21.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current Total Equity is A$21.48 Mil. Starpharma Holdings' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Total Equity is A$21.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Total Equity: A$21.48 Mil
  • GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
52GF Score

Get the complete analysis for ASX:SPL

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.70
Price
A$0.43
GF Value